Please Wait
Applying Filters...
menu
    • menu
    FDA approvals drop 8% in 2025, with fewer blockbusters; Brinsupri, Rhapsido make it to first-in-class list

    Data Compilation
    #PharmaFlow

    Pipeline Prospector Jan 2026 highlights: Astra, CSPC sign up to US$ 18.5 bn obesity deal; Wegovy’s pill version debuts in US

    Stock Recap
    #PipelineProspector

    Menu

    laserphyrin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    MARKET PLACE

    PharmaCompass
    Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Log in to download the data

    Last Updated on PharmaCompass Virtual Booth Country Holder DMF No. Subject Submission Date Status Type GDUFA DMF Review GDUFA Review Date GDUFA Payment Date
    27/02/2026 LIGHT SCIENCES ONCOLOGY INC
    U.S.A
    		 LIGHT SCIENCES ONCOLOGY INC 22405 TALAPORFIN SODIUM (LS11) LYOPHILIZED DRUG PRODUCT FORMULATION AND FILLING 2009-01-15 Active II N/A
    27/02/2026 LIGHT SCIENCES ONCOLOGY INC
    U.S.A
    		 LIGHT SCIENCES ONCOLOGY INC 18775 TALAPORFIN SODIUM (LS11) LYOPHILIZED DRUG PRODUCT 2005-09-15 Inactive II N/A
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.